Companies › Isomorphic Labs
Isomorphic Labs logo

Isomorphic Labs

London, GB · ≈269 employees · Research and Development in Biotechnology (except Nanobiotechnology) · Crunchbase rank #635 · isomorphiclabs.com

Isomorphic Labs is an AI-first drug design and development company that transforms drug discovery by using machine learning to design and evaluate new medicines. It builds on research from DeepMind, including the AlphaFold system, which is used to predict protein structures and understand how biological molecules interact. The company develops AI models that simulate biological processes and support the design of drug candidates across multiple disease areas. Its platform integrates predictive and generative AI systems to explore chemical space, identify therapeutic targets, and propose new molecular structures with potential medical applications. It collaborates with pharmaceutical companies on research programs in areas such as oncology and immunology, with the aim of accelerating early-stage drug discovery and improving candidate selection. The organization also develops internal pipelines of AI-designed drug candidates and is progressing toward clinical testing of its first programs. Its work combines computational biology, medicinal chemistry, and machine learning to support end-to-end drug design workflows, from target identification to preclinical evaluation.

Funding

1
Every round, secondary, debt facility or acquisition involving Isomorphic Labs that AI Lounge tracks, newest first. Latest: Series B on May 12, 2026.
Isomorphic Labs logo
Thrive Capital (lead), Google (lead), CapitalG, MGX, Temasek · AI drug discovery
$2.1B

Timeline · 4

In the news

3
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in